BR112014032987A2 - method of treatment or prophylaxis of a neurological disorder - Google Patents

method of treatment or prophylaxis of a neurological disorder

Info

Publication number
BR112014032987A2
BR112014032987A2 BR112014032987A BR112014032987A BR112014032987A2 BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2 BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A BR112014032987 A BR 112014032987A BR 112014032987 A2 BR112014032987 A2 BR 112014032987A2
Authority
BR
Brazil
Prior art keywords
prophylaxis
treatment
neurological disorder
œmethod
ago
Prior art date
Application number
BR112014032987A
Other languages
Portuguese (pt)
Inventor
Krull David
Bullman Jonathan
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112014032987A2 publication Critical patent/BR112014032987A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

1 / 1 resumo “ mã‰todo de tratamento ou profilaxia de um distãšrbio neurolã“gico â€� a invenã§ã£o refere-se a um mã©todo de tratamento ou profilaxia de um distãºrbio neurolã³gico, em particular, mas nã£o exclusivamente, a esclerose lateral amiotrã³fica (ela), que compreende a administraã§ã£o de um anticorpo anti-nogo-a.1/1 summary â € œMethod of treatment or prophylaxis of a neurological disorder â € “the invention relates to a method of treatment or prophylaxis of a particular neurological disorder but not exclusively, amyotrophic lateral sclerosis (she), which comprises the administration of an anti-ago-antibody.

BR112014032987A 2012-07-05 2013-07-03 method of treatment or prophylaxis of a neurological disorder BR112014032987A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261668134P 2012-07-05 2012-07-05
PCT/EP2013/064063 WO2014006105A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
BR112014032987A2 true BR112014032987A2 (en) 2017-06-27

Family

ID=48741180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014032987A BR112014032987A2 (en) 2012-07-05 2013-07-03 method of treatment or prophylaxis of a neurological disorder

Country Status (10)

Country Link
EP (1) EP2870177A1 (en)
JP (1) JP2015521992A (en)
KR (1) KR20150036398A (en)
CN (1) CN104395343A (en)
AU (1) AU2013285493A1 (en)
BR (1) BR112014032987A2 (en)
CA (1) CA2876284A1 (en)
IN (1) IN2014KN02952A (en)
RU (1) RU2014150265A (en)
WO (1) WO2014006105A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279751B1 (en) * 2019-06-28 2021-07-21 경북대학교 산학협력단 Composition for diagnosis of myopathy comprising an agent for determining the level of NOGO-A gene or myogenic factor and method for diagnosing myopathy using the same
KR102409771B1 (en) * 2020-06-17 2022-06-16 경북대학교 산학협력단 Method for screening therapeutic agents for muscle diseases using the mutual coupling of Nogo-A and Filamine-C

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10336350B4 (en) 2003-08-08 2007-10-31 Westfalia Separator Ag Solid bowl centrifuge, with paring disc
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
TWI329649B (en) 2003-12-22 2010-09-01 Glaxo Group Ltd Immunoglobulins
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
BRPI0818928B1 (en) 2007-11-02 2021-12-07 Novartis Ag ISOLATED NOGO-A BINDING MOLECULES, THEIR PRODUCTION METHOD AND USE, ISOLATED POLYNUCLEOTIDE, VECTOR AND EXPRESSION SYSTEM, ISOLATED HOST CELL, AND PHARMACEUTICAL COMPOSITION
JP2011527317A (en) 2008-07-11 2011-10-27 グラクソ グループ リミテッド Treatment of amyotrophic lateral sclerosis with NOGO-A antagonist

Also Published As

Publication number Publication date
JP2015521992A (en) 2015-08-03
IN2014KN02952A (en) 2015-05-08
RU2014150265A (en) 2016-08-27
AU2013285493A1 (en) 2015-01-22
EP2870177A1 (en) 2015-05-13
CN104395343A (en) 2015-03-04
CA2876284A1 (en) 2014-01-09
WO2014006105A1 (en) 2014-01-09
KR20150036398A (en) 2015-04-07

Similar Documents

Publication Publication Date Title
PH12017500987A1 (en) Heating element module for an aerosol-generating device
SG10201903962PA (en) Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
MX2016017355A (en) Lipid comprising docosapentaenoic acid.
TR201811764T4 (en) Aminoheteroaryl benzamides as kinase inhibitors.
BR112015024674A2 (en) method for enhancing the survivability of one or more beneficial microorganisms and for coating a seed, and, composition
NZ715815A (en) High-stability t-cell receptor and preparation method and application thereof
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
MX2015008766A (en) Fluorinated cbd compounds, compositions and uses thereof.
BR112013000768A2 (en) basidiomycete asparaginase
MX2014010959A (en) Phosphoric ester preparations with reduced hygroscopicity.
EA201590744A1 (en) TORRING OF TOR CANCER BY KINASE INHIBITORS
PH12016500903A1 (en) Novel methods for treating neurodegenerative diseases
EA201491581A1 (en) ВЕЗИКУЛЯРНЫЕ КОМПОЗИЦИИ
BR112014032987A2 (en) method of treatment or prophylaxis of a neurological disorder
CL2015002069A1 (en) Methods for the use of phenoxypropylamine compounds to treat depression.
MX338405B (en) 2-iminobiotin formulations and uses thereof.
MX2013000539A (en) New formulations of 14 - epi -analogues of vitamin d.
EA201691036A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
EA201690914A1 (en) NEW CONNECTION FOR THE TREATMENT OF HEAVY HYPOGLYCEMIA
MX2015017880A (en) Method for preventing and/or treating chronic traumatic encephalopathy-i.
BR112015020874A2 (en) Internet-accessible resource group ownership
MX2015006616A (en) Dual targeting.
IN2013MU01219A (en)
PH12016500541A1 (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
UA114811C2 (en) New compositions for treating amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 4A ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)